Type
1.
Illarramendi X, Oliveira MLW- del-R de, Sales AM, Costa Nery JA, Sarno EN. Considerations on clinical trials of leprosy treatment: need of novel drug combinations. Clinical Investigation [Internet]. 2013;3(7):617-35. Available from: http://www.future-science.com/doi/pdf/10.4155/cli.13.52
Type
1.
Lakshmi C, Srinivas CR. Lepromatous leprosy treated with combined chemotherapy and immunotherapy (injection BCG): three case reports. International journal of dermatology. 2013;.
Type
1.
Jian-Ping S, Wen-Zhong L. [Activity of Home-made Pefioxacin M.Leprae In Mice and Its Preliminary Effecto in the Treatment of Multibaciilary Leprosy]. Chinese Journal of Dermatology [Internet]. 1992;25(1):25-8. Available from: http://manu16.magtech.com.cn/Jwk_cmazp/EN/abstract/abstract23233.shtml
Type
1.
[Observation on the therapeutic effect of isobutylpiperazinyl rifamycin (R761) in treating lepromatous leprosy]. Chinese Journal of Dermatology [Internet]. 1983;16(4):223-7. Available from: http://manu16.magtech.com.cn/Jwk_cmazp/EN/abstract/abstract20834.shtml
Type
1.
Wen-Zhong L, Gan-Yun Y. [Effect of treatment with Rifampicin, Clofazimine and Dapsone in multibacillary leprosy in the field for three years]. Chinese Journal of Dermatology. 1988;21(5):265-8.
Type
1.
Wen-Zhong L, Gan-Yun Y. [Results of six-month treatment of paucibacillary leprosy patients with rifampicin and dapsone]. Chinese Journal of Dermatology. 1988;21(6):355-7.
Type
1.
Vargas LCO, Rueda AG, Becerra X, Moreno EJ, León LDS. [Associated factors with irregular intake of Dapsone in leprosy patients]. Revista de la Universidad Industrial de Santander. Salud [Internet]. 2013;45(1):7-14. Available from: http://www.scielo.org.co/pdf/suis/v45n1/v45n1a02.pdf
Type
1.
Oliveira DT, Sherlock J, Melo EV, Rollemberg KCV, Paixão TRS, Abuawad YG, et al. Clinical variables associated with leprosy reactions and persistence of physical impairment. Revista da Sociedade Brasileira de Medicina Tropical [Internet]. 2013;46(5):600-4. Available from: http://www.scielo.br/pdf/rsbmt/v46n5/0037-8682-rsbmt-42-2013.pdf
Type
1.
Koval, Vlasov, Shichkova, Khunderyakova, Markov, Panchenko, et al. Anti-leprosy drug Clofazimine inhibits growth of triple-negative breast cancer cells via inhibition of canonical Wnt signaling. Biochemical pharmacology. 2013;.
Type
1.
Chakraborty, Chakraborty, Sengupta. Successful treatment of osteomyelitis in leprosy patients by homeopathic medicine. Exploratory Animal and Medical Research [Internet]. 2013;3(2):169-77. Available from: http://animalmedicalresearch.org/Vol.3_Issue-2_December_2013/D%20Chakraborty.pdf